{"links":{"html":"https://www.erudio.com/reports/pivot-09-nct03729245","json":"https://www.erudio.com/reports/pivot-09-nct03729245.json","markdown":"https://www.erudio.com/reports/pivot-09-nct03729245.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"pivot-09-03729245"}},"request":"https://www.erudio.com/contact?report=pivot-09-03729245"},"offer":{"cited_commentary_sources":8,"verified_hcp_statements":27,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":5,"optional":true,"price_per_verified_person_usd":15,"price_usd":75,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"pivot-09-nct03729245"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=pivot-09-03729245","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/pivot-09-nct03729245","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-30T16:53:14.121874Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: the sample findings; the report description."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC"},{"claim_count":4,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC"},{"claim_count":2,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":1,"title":"Secondary endpoint: Progression Free Survival (PFS) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":1,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":1,"coverage":"discussed","id":"A1","source_count":1,"title":"Tentative biomarker benefit and the need for better selection"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":1,"title":"Advanced-RCC treatment-selection context and cross-trial caution"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Perceived scientific and collaborative value"}],"counts":{"cited_sources":11,"claims_by_expression_type":{"comparison":3,"experience":1,"interpretation":3,"opinion":5,"primary_context":12,"question":1,"restatement":2},"claims_by_kind":{"objective_result":2,"protocol_statement":10,"source_observation":15},"clinician_statements":2,"evidence_units":24,"findings":5,"organisational_accounts":1,"people_cited":6,"people_identity_verified":5,"people_total":6,"screened_sources":18,"verified_claims":27},"findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":3,"experience":1,"questions":0,"restated":3,"views":2},"has_counterview":false,"limitations":3,"links":{"context":3,"support":9},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"Regimen-specific efficacy caution accompanies reports of fewer high-grade adverse events."},{"id":"F2","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"The usefulness of a single-agent TKI control was questioned"},{"id":"F3","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"The possible PD-L1 subgroup benefit remains a selection hypothesis"},{"id":"F4","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Broader advanced-RCC commentary emphasizes patient priorities and cross-trial caution"},{"id":"F5","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":false,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Recognition of the trial’s contribution is distinct from efficacy endorsement"}],"medical_affairs_question":"How should Medical Affairs explain comparator relevance and regimen-specific benefit–risk without turning null comparisons or a tentative subgroup signal into equivalence or a selection rule?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Regimen-specific efficacy caution, with a qualified safety trade-off"},{"id":"section-2","level":2,"title":"Whether the control answered the evolving clinical question"},{"id":"section-3","level":2,"title":"A tentative subgroup exception, not a biomarker rule"},{"id":"section-4","level":2,"title":"Advanced-RCC selection context: patient priorities and limits of comparison"},{"id":"section-5","level":2,"title":"Scientific and collaborative value without a positive efficacy claim"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2}],"id":"T1","label":"Primary endpoint: Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T2","label":"Primary endpoint: Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T3","label":"Secondary endpoint: Progression Free Survival (PFS) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC"},{"findings":[{"id":"F4","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-30T16:53:14.121874Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-30T17:42:37Z","record_hash":"fdb4a1a5134cc3506b8c683ccabfc30119b16d94524cd1efbbee1ed8bd6860cb","release_hash":"cb24ad937aa058a864aab8fb11f24f401e3769978aa639f083106e64b8f2e55d","report_id":"erudio-nct03729245","run_id":"c3d7ca18-f6ef-4633-889f-1a6d67ea844e","schema_version":"5.0","slug":"pivot-09-03729245","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PIVOT-09 asks whether bempegaldesleukin plus nivolumab improves response and survival over single-agent sunitinib or cabozantinib as initial therapy for advanced renal cell carcinoma. Commentary comes from X posts; clinical roles are not confirmed in the sources reviewed for this edition. The discussion turns on one speaker’s regimen-specific efficacy caution alongside reports of fewer high-grade adverse events, whether a possible PD-L1 subgroup benefit can guide selection, and how recognition of the trial’s contribution differs from efficacy endorsement.","meta_description":"18 sources screened · 27 verified statements (2 from clinicians verified by NPI or staff page) from 11 sources · 5 findings. Updated Oct 30, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-02ec4fcb12206f776a6d","claim-b20d9b4ed2ce018353ac","claim-b16f3ae0361761573c93"],"id":"F1","paraphrase":"How are response, survival and adverse events compared in an X thread relaying the trial presentation?","source_channel":"x_thread","source_date":"2022-09-12","title":"Regimen-specific efficacy caution accompanies reports of fewer high-grade adverse events."},{"cited_claim_ids":["claim-b20d9b4ed2ce018353ac","claim-f6ca723e7a6d67288abf"],"id":"F3","paraphrase":"What patient-selection questions do X posts raise about biomarkers in this treatment setting?","source_channel":"x_thread","source_date":"2022-09-12","title":"The possible PD-L1 subgroup benefit remains a selection hypothesis"}]},"publication":{"approved_at":"2026-10-30T17:42:37Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-30T23:47:02Z","summary":"Corrected to match the delivered report: the sample findings; the report description."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":18},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are a selective set of public discussions, not a representative assessment of HCP opinion.","Discussion omitting the trial name or using other shorthand may be absent. Some potentially relevant discussions were not read, and some passages were not fully assessed, so additional viewpoints may be missing.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The presentation and publication summaries relayed by a speaker are not independent analyses by the speaker. Circulation through reposts does not establish additional authors’ endorsement.","The posts often omit numerical estimates, risk-population details and statistical qualifications; the tentative subgroup statement is especially limited."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":2,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":8,"methods":2,"results":1},"count":11,"evidence_window":{"end":"2024-06-10","start":"2019-02-12"},"retrieval_snapshot":"2026-10-30T16:15:45.042723Z","timeline":[{"count":1,"week":"2019-W07"},{"count":1,"week":"2019-W08"},{"count":1,"week":"2021-W46"},{"count":2,"week":"2022-W37"},{"count":3,"week":"2024-W23"},{"count":1,"week":"2024-W24"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT03729245:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03729245:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03729245:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03729245:protocol:1","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT03729245:sap:2","quote_policy":"short_quote_link_out"},{"id":"pubmed:38838287","quote_policy":"short_quote_link_out"},{"id":"openfda:43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c:20260220","quote_policy":"short_quote_link_out"},{"id":"openfda:f570b9c4-6846-4de2-abfa-4d0a4ae4e394:20260812","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1095333805659803648:ec157b05-5651-4a8b-9feb-6e6181eb9037","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1097862658479607812:ab8cb2e7-31bd-4d85-88a3-72da634489af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1325074859504840705:83a51460-19b4-4e11-aeef-1d87375894f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1418292151356583936:596465c6-2acb-40ea-b137-d1fc5c849e02","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1446490033104502789:4fc773bc-b188-4590-b732-49a33b875ee3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1461471452985659396:a2d3f958-d444-4cbb-a6e3-2e673d2d017a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1461796903654502401:96a7601b-209b-4615-afd5-7080913abd1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1495111802690043905:192f41d1-85d8-4a78-8f18-3f9faf83283a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1516174976319168518:85ab0c7f-ff14-41a4-ae66-06715c808ff9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568126499638898688:3e980d6f-19de-416e-9a6a-358d61597145","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1569309059215462401:f6f214bb-3625-42be-8701-11801b4b70d7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1569315663663239170:c5c4a2ef-e81e-4618-8bcd-115b9315cc76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1798724086467821801:07f7c0d6-1bfe-4e27-8ef9-ed3dad7157e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1798763127376580976:1e86845b-f412-487c-8072-61f4127a315f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1798810489948160240:44d12e8d-e527-469d-8cb7-125ff70feb1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1798962425359683724:04be6c0e-eb2c-4188-8d0a-e40989c74965","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1799055101476438139:06f663a2-fb13-4a56-aeb0-3aa59d501f25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1799487415167664242:34417ea4-5455-4aaa-b2d6-bdf9c15639b2","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2024-06-10","start":"2019-02-12"},"retrieval_snapshot":"2026-10-30T16:15:45.042723Z","timeline":[{"count":1,"week":"2019-W07"},{"count":1,"week":"2019-W08"},{"count":1,"week":"2020-W45"},{"count":1,"week":"2021-W29"},{"count":1,"week":"2021-W40"},{"count":2,"week":"2021-W46"},{"count":1,"week":"2022-W07"},{"count":1,"week":"2022-W16"},{"count":1,"week":"2022-W36"},{"count":2,"week":"2022-W37"},{"count":6,"week":"2024-W23"},{"count":1,"week":"2024-W24"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: bempegaldesleukin","status":"unmapped"},{"brand_names":["Sutent"],"label":"sunitinib","slug":"sunitinib"},{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":["Cabometyx","Cometriq"],"label":"cabozantinib","slug":"cabozantinib"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PIVOT-09","aliases":["PIVOT-09","CA045002","A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma"],"brief_title":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","collaborators":["Bristol-Myers Squibb"],"conditions":["Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma"],"display_condition":"previously untreated advanced clear cell renal cell carcinoma","display_interventions":[["bempegaldesleukin","nivolumab"]],"enrollment":{"count":623,"type":"ACTUAL"},"interventions":[{"name":"bempegaldesleukin","synonyms":["BEMPEG","BMS-986321"],"type":"BIOLOGICAL"},{"name":"sunitinib","synonyms":["Sutent®"],"type":"DRUG"},{"name":"nivolumab","synonyms":["Opdivo®","BMS-936558"],"type":"BIOLOGICAL"},{"name":"cabozantinib","synonyms":["Cabometyx®"],"type":"DRUG"}],"nct_id":"NCT03729245","official_title":"A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma","overall_status":"TERMINATED","phase":["PHASE3"],"primary_completion_date":{"date":"2022-01-07","type":"ACTUAL"},"primary_endpoints":[{"description":"ORR using modified Response Evaluation Criteria in Solid Tumors (mRECIST) 1.1 by Blinded Independent Central Review (BICR) in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) All-risk patients and intermediate- or poor-risk patients. ORR is defined as the proportion of enrolled participants who achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR). CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to \\<10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR.","measure":"Objective Response Rate (ORR) Per mRECIST 1.1 by BICR in IMDC All-risk Patients and Intermediate- or Poor (I/P)-Risk Patients With Previously Untreated Advanced RCC","timeFrame":"Approximately 32 months"},{"description":"OS is defined as the time from date of first dose to the date of death from any cause. Patients without a date of death were censored at their last known alive date.","measure":"Overall Survival (OS) in IMDC All-Risk and Intermediate- or Poor-risk Patients With Previously Untreated Advanced RCC","timeFrame":"Approximately 32 months"}],"registered_date":{"date":"2018-11-02","type":"ACTUAL"},"registry_last_updated":"2023-04-11","registry_url":"https://clinicaltrials.gov/study/NCT03729245","short_name":"PIVOT-09","short_name_basis":"canonical_name","sponsor":"Nektar Therapeutics","start_date":{"date":"2018-12-18","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"17-214-09","type":"sponsor_study_id"},{"domain":"Bristol-Myers Squibb Protocol ID","id":"CA045002","type":"other"}],"study_type":"INTERVENTIONAL"}}}